Home > Compound List > Product Information
Biperiden_Molecular_structure_CAS_514-65-8)
Click picture or here to close

Biperiden

Catalog No. DB00810 Name DrugBank
CAS Number 514-65-8 Website http://www.ualberta.ca/
M. F. C21H29NO Telephone (780) 492-3111
M. W. 311.46106 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 689

SYNONYMS

IUPAC name
1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol
IUPAC Traditional name
biperidene
Brand Name
Akineton
Akinophyl
Synonyms
Biperidenum [INN-Latin]
Biperideno [INN-Spanish]
Biperiden Hydrochloride
Biperidene Hydrochloride
Biperiden [Usan:Ban:Inn:Jan]
Biperidene [INN-French]
Biperidine
Biperidine Hydrochloride
Beperiden

DATABASE IDS

CAS Number 514-65-8
PubChem SID 46508325
PubChem CID 2381

PROPERTIES

Hydrophobicity(logP) 4.1
Solubility 25.1 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem]
Indication For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.
Pharmacology Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control.
Toxicity LD50=760 mg/kg (Orally in rats). Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Affected Organisms
Humans and other mammals
Biotransformation The metabolism of biperiden is not completely understood, but does involve hydroxylation.
Absorption 87% bioavailability
Protein Binding 60%
References
Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Nishiyama K, Mizuno T, Sakuta M, Kurisaki H: Chronic dementia in Parkinson's disease treated by anticholinergic agents. Neuropsychological and neuroradiological examination. Adv Neurol. 1993;60:479-83. Pubmed